NMS·Healthcare·$1.0B·#41 / 520 in Healthcare
PHAT Phathom Pharmaceuticals, Inc.
73SOLID
CATEGORY BREAKDOWN
GROWTH100
QUALITY100
STABILITY51
VALUATION71
GOVERNANCE34
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+216.9%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
87.1%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
9 months
27
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-48.3%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
4.9x
71
< 3x strong
Rule of 40
Growth rate plus operating margin
126
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.6%
36
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+13.3%
30
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PHAT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PHAT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.